Recombinant AAV serotype 1 transduction efficiency and tropism in the murine brain
- 1 August 2003
- journal article
- research article
- Published by Springer Nature in Gene Therapy
- Vol. 10 (17) , 1528-1534
- https://doi.org/10.1038/sj.gt.3302011
Abstract
Recombinant adeno-associated virus serotype 2 (rAAV2) vectors have shown promise as therapeutic agents for neurologic disorders. However, intracerebral administration of this vector leads to preferential transduction of neurons and a restricted region of transgene expression. The recently developed rAAV vectors based upon nonserotype 2 viruses have the potential to overcome these limitations. Therefore, we directly compared a rAAV type 1 to a type 2 vector in the murine brain. The vectors were engineered to carry identical genomes (AAV2 terminal repeat elements flanking an enhanced green fluorescent protein expression cassette) and were administered by stereotaxic-guided intracerebral injection. We found that the rAAV1 vector (rAAV1-GFP) had a 13- to 35-fold greater transduction efficiency than that of the rAAV2 vector (rAAV2-GFP). Also, rAAV1-transduced cells were observed at a greater distance from the injection site than rAAV2-transduced cells. Neurons were the predominant cell type transduced by both vector types. However, in contrast to rAAV2-GFP, rAAV1-GFP was capable of transducing glial and ependymal cells. Thus, rAAV1-based vectors have biologic properties within the brain distinct from that of rAAV2. These differences might be capitalized upon to develop novel gene transfer strategies for neurologic disorders.Keywords
This publication has 45 references indexed in Scilit:
- Combined Injection of rAAV with Mannitol Enhances Gene Expression in the Rat BrainMolecular Therapy, 2001
- Recombinant Adeno-Associated Virus-Mediated Correction of Lysosomal Storage within the Central Nervous System of the Adult Mucopolysaccharidosis Type VII MouseHuman Gene Therapy, 2000
- Sustained Production of β-Glucuronidase from Localized Sites after AAV Vector Gene Transfer Results in Widespread Distribution of Enzyme and Reversal of Lysosomal Storage Lesions in a Large Volume of Brain in Mucopolysaccharidosis VII MiceExperimental Neurology, 1999
- Adeno-Associated Virus-Mediated Gene Transfer to the Brain: Duration and Modulation of ExpressionHuman Gene Therapy, 1999
- Gene Transfer into the CNS Using Recombinant Adeno-associated Virus: Analysis of Vector DNA Forms Resulting in Sustained ExpressionJournal of Drug Targeting, 1999
- Behavioral Recovery in 6-Hydroxydopamine-Lesioned Rats by Cotransduction of Striatum with Tyrosine Hydroxylase and Aromatic l-Amino Acid Decarboxylase Genes Using Two Separate Adeno-Associated Virus VectorsHuman Gene Therapy, 1998
- In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vectorGene Therapy, 1998
- Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson’s disease in ratsProceedings of the National Academy of Sciences, 1997
- Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vectorBrain Research, 1996
- Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brainNature Genetics, 1994